Efficacy of cabergoline in the management of prolactinoma
Keywords:
Dopamine agonists, cabergoline, prolactinomaAbstract
Prolactinomas are first-line drug treatment, which in most cases is required in optimal doses to achieve treatment goals, and this dose has also been shown to be safe; however, in patients in whom no response is evidenced, raising the dose may be considered for the drug to be effective and this population will probably be more prone to developing adverse effects.
Objective: To determine the efficacy of cabergoline in the management of prolactinoma.
Materials and methods: retrospective, descriptive, comparative, observational, longitudinal study, of 42 patients with prolactinomas treated at the "Hospital de Especialidades Guayaquil, Doctor Abel Gilbert Pontón", in the period January to September 2020, data management was performed in sheets Microsoft Excel 2010 calculation program, where data processing was performed and the SPSS version 23 program was used for statistical analysis.
Results: 100% received cabergoline, 19% required doses greater than 2mg / week, demonstrating clinical benefit, especially with cabergoline alone and in low doses except for visual field alterations, the normalization of prolactin was achieved in 81%, the majority with low doses, the reduction of tumor size occurred in 100% of the patients, being effective all the schemes of Treatment studied, 17% presented adverse effects and most were resolved, no valvular disease was evident.
Conclusions: Cabergoline therapy in the management of prolactinomas is effective and safe in low doses.
References
Ahlquist, J. (2019). Diagnosis of Prolactinoma and Causes of Hyperprolactinemia. Elsevier Inc.
Al-Chalabi, M., Bass, A., & Alsalman, I. (2020). Physiology, Prolactin. StatPearls.
Almalki, M., Aljohani, N., Alzahr, S., Almohareb, O., Ahmad1, M., Alshahrani, F., & Mahmood , B. (2020). Clinical Features, Therapeutic Trends, and Outcome of Giant Prolactinomas: A Single-Center Experience Over a 12-Year Period.
Auriemma , R., Grasso, L., Pivonello , R., & Colao , A. (2016). The safety of treatments for prolactinomas. Journa Expert Opinion on Drug Safetyl.
Auriemma, R., Pirchio, R., De Alcubierr, D., Colao, A., & Pivonello, R. (2019). Dopamine Agonists: From the 1970s to Today. Neuroendocrinology.
Bhavsar, K., & Silver, K. (2019). Cystic Prolactinoma: A Surgical Disease? AACE Clinical Case Reports.
Caputo, C., & Inder, W. (2019). J Clin Endocrinol Metab.
Caputo, C., Prior, D., & Inder, W. (2018). The Third Case of Cabergoline-Associated Valvulopathy: The Value of Routine Cardiovascular Examination for Screening. JES Journal of the Endocrine Society.
Cevallos, A. (2018). Prolactinomas predictores de remisión y recurrencia después del retiro de los agonistas dopaminérgicos.
Chanson, P., & Maiter, D. (2019). The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Best Practice & Research Clinical Endocrinology & Metabolism.
Chávez , M., Jimenez, M., Armijo, M., Dominguez, J., Gongora, K., Guerra, S., & Sandoval, L. (2018). Update Treatment for Prolactinoma. International Journal of Innovative Research in Medical Science.
Chen , A., & Burt, M. (2017). Hyperprolactinaemia. Aust Prescr.
Cocks, D., Javanmard, P., Cox, K., & Geer, E. (2018). Prolactinoma through the female life cycle. Endocrine.
Donoho, D., & Laws, E. (2019). The Role of Surgery in the Management of Prolactinomas. Neurosurg Clin N Am.
Farah, A., Zunera, T., Dana, E., & Diane, D. (2020). Association between prolactinoma and body mass index. Endocrine Practice.
Fröhlich , E., & Wahl, R. (2019). The forgotten effects of thyrotropin-releasing hormone: Metabolic functions and medical applications. Front Neuroendocrino.
Fuentes , N. (2018). Caracterización clínica y de laboratorio de los pacientes con diagnóstico de Prolactinoma en el Hospital de Especialidades Eugenio Espejo durante el periodo.
Gheorghiu, M., Negreanu, F., & Fleseriu, M. (2019). Updates in the Medical Treatment of Pituitary Adenomas.
Hofler, R., Ann Emanuele, M., Samarasinghe, S., Shah, L., Melian, E., & Barton, K. (2016). Prolactinoma: Part III—Surgery, Radiation, and Chemotherapy.
Huang, H., Shao , L., Wei, Z., & Wu, Z. (2018). Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review. Metabolic Brain Disease.
Ji, L., Yi , N., Zhang , Q., Zhang , S., Liu, X., Shi , H., & Lu, B. (2018). Management of prolactinoma: a survey of endocrinologists in China. Endocrine conections.
Levine, S., & Muneyyirci-Delale, O. (2018). Stress-Induced Hyperprolactinemia: Pathophysiology and Clinical Approach. Obstetrics and Ginecology International.
Liu, X., Tang, C., Wen, G., Zhong, C., Yang, J., Zhu, J., & Ma, C. (2019). The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas. Front Endocrinol.
Lopes, B. (2019). Pathology of prolactinomas: any predictive value? Pituitary.
López, C., Gaviria, J., Henao, R., & Piedrahíta, D. (2016). Características clínicas y presencia de prolactinoma en mujeres con hiperprolactinemia. IATREIA.
Macotela , Y., Triebel , J., & Clapp, C. (2020). Time for a New Perspective on Prolactin in Metabolism. Trends Endocrinol Metab.
Magalhães, M., Castro, L., Naves, L., Mendonça, J., de Lima, B., Kessler, I., & Casulari, L. (2018). Prolactinomas Resistant to Treatment With Dopamine Agonists: Long-Term Follow-Up of Six Cases. Front. Endocrinol.
Maiter, D. (2019). Management of Dopamine Agonist-Resistant Prolactinoma. Neuroendocrinology.
Manterolaa, C., Quirozb, G., Salazarb, P., & García, N. (2019). Metodología de los tipos y diseños de estudio más frecuentemente utilizados en investigación clínica. Revista Médica Clínica Las Condes.
Martin, N. (2017). Prolactin disorders. Medicine.
Melgar, V., Espinosa, E., Sosa, E., Rngel, M., Cuenca, D., Ramirez, C., & Mercado, M. (2016). Current diagnosis and treatment of hyperprolactinemia. Diagnóstico y tratamiento actual de la hiperprolactinemia.
Michail, M., Ioannis, K., Charoula, M., Trivli , A., & Hatzidaki, E. (2019). Clinical manifestations, evaluation and management of hyperprolactinemia in adolescent and young girls: a brief review. Acta Biomed.
Mitrofanova, L., Konovalov, P., Krylova, J., Polyakova, V., & Kvetnoy, I. (2017). Plurihormonal cells of normal anterior pituitary: Facts and conclusions. Oncotarget.
Mohan, N., Chia, Y., Hean , G., Ting,, E., Teo, K., & Tsai , T. (2017). Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective. BMJ Case Rep.
Molitch, M., Drummond, J., & Korbonits, M. (2018). Prolactinoma Management. Endotext.
Nunes-Nogueira, V., Gomes, P., da Silva, E., & Atallah, A. (2018). Dopamine agonists for idiopathic hyperprolactinaemia and prolactinoma in adults. Cochrane Library.
Petersenn, S. (2019). Biochemical diagnosis in prolactinomas: some caveats. Pituitary.
Puma , M. (2017). Dopaminergicos en pacientes con hiperprolactinemia y/o acromegalia no incrementa el numero de valvulopatias cardiacas clinicamente significativas.
Ranganathan , P., & Aggarwal, R. (2018). Study designs: Part 1 – An overview and classification. Perspect Clin Res.
Sahakian, N., Castinetti, F., Dufou, H., Graillon, T., Romanet, P., Barlier, A., . . . Cuny, T. (2019). Clinical management of difficult to treat. HAL.
Saleem , M., Martin , H., & Coate, P. (2018). Prolactin Biology and Laboratory Measurement: An Update on Physiology and Current Analytical Issues. Clin Biochem Rev.
Samarasinghe, S., Emanuele, M. A., Hofler, R., Shah, L., Nucifora, P., Borys, E., & Prabhu, V. (2016). Prolactinoma: Part I—Clinical Presentation, Radiology, and Histopathology. Contemporary Neurosurgery.
Samperi, I., Lithgow, K., & Karavitaki, N. (2019). Hyperprolactinaemia. J Clin Med.
Sergeevna, F. (2018). Características clínicas y morfológicas de los tumores hipofisarios secretores de prolactina resistentes al tratamiento con agonistas dopaminérgicos.
Song , Y., Chen, M., Lian , W., Xing, B., Yao, Y., Feng, M., & Wang, R. (2017). Surgical treatment for male prolactinoma. Journal List.
Šostarić, M., Bokulić, A., Marijančević, D., & Zec, I. (2019). Optimizing laboratory defined macroprolactin algorithm. Biochem Med.
Soto, E., Newey, P., Bevan , J., & Leese, G. (2017). Morbidity and mortality in patients with hyperprolactinaemia: the PROLEARS study. European Society of Endocrinology.
Souteiro, P., & Karavitaki, N. (2020). Dopamine agonist resistant prolactinomas: any alternative medical treatment? Pituitary.
Strauss , J., Barbieri , R., & Gargiulo, A. (2018). Yen & Jaffe's Reproductive Endocrinology. Elsevier.
Thapa, S., & Bhusal, K. (2020). Hyperprolactinemia. StatPearls .
Torner, L. (2016). Actions of Prolactin in the Brain: From Physiological Adaptations to Stress and Neurogenesis to Psychopathology. Front Endocrinol.
Vroonen , L., Daly , A., & Beckers, A. (2019). Epidemiology and Management Challenges in Prolactinomas. Neuroendocrinology.
Yatavelli, R. K., & Bhusal., K. (2020). StatPearls. Prolactinoma.
Zielinski, G., Ozdarski, M., Maksymowicz, M., Szamotulska, K., & Witek, P. (2020). Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery. Front. Endocrinol.
Xia , M., Lou, X., Lin , S., & Wo, Z. (2018). Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis.
